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Diabetic nephropathy is the most common cause of glomerulosclerosis and end-stage renal disease (ESRD) \[[@B1]\]. Between 20 and 40% of patients with diabetes mellitus ultimately develop nephropathy \[[@B2]\]. The standard of care for diabetic nephropathy has been blood pressure control, the use of renin-angiotensin system-blocking agents such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), and tight glycemic control \[[@B3]\]. However, current therapeutic strategies are far from being completely effective because no available therapy successfully prevents diabetic nephropathy and many patients still progress to ESRD.

In a recent short-term study, the direct renin inhibitor aliskiren held promise as it further reduced the urinary albumin-to-creatinine ratio (ACR) when added to losartan \[[@B4]\]; however, the long-awaited ALTITUDE trial examining the effects of aliskiren when added to ACEI/ARB on long-term renal and cardiovascular outcomes has been recently halted because of an increased incidence of adverse events including nonfatal strokes in the aliskiren group \[[@B5]\]. Therefore, there is need for new therapies that would target other primary mechanisms that are implicated in the pathogenesis of diabetic nephropathy. In fact, recent advances in the understanding of the pathophysiologic mechanisms of diabetic kidney disease have led to the clinical development of new therapeutic agents, many of which are currently the subject of ongoing clinical trials.

In this review, we focus on some of the recently completed clinical trials involving novel drugs that hold promise for the management of diabetic nephropathy.

Pirfenidone {#sec1_2}
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Pirfenidone is an orally bioavailable compound that has been found to inhibit transforming growth factor-β (TGF-β) production and consequent matrix deposition in experimental animal models of lung and kidney disease \[[@B6]\]. In a recent randomized double-blind placebo-controlled trial \[[@B7]\], 77 subjects with diabetes, reduced estimated glomerular filtration rate (eGFR), and proteinuria were enrolled and randomized to one of the three study arms (placebo, pirfenidone 1,200 mg daily, and pirfenidone 2,400 mg daily). The primary end point was the change in eGFR in individual subjects from baseline to the end of the study. After 54 weeks, there was an improvement in eGFR in the pirfenidone 1,200 mg group, with a net increase of 3.3 ml/min/1.73 m^2^. The pirfenidone 2,400 mg group had an intermediate change in eGFR (−1.9 ml/min/1.73 m^2^) that was not significantly different compared with the placebo arm. Interestingly, there were no significant differences among the study groups in the change in urinary ACR from baseline to the end of the study.

Limitations of the above study included the lack of hard renal and clinical end points such as progression to ESRD and death, a high dropout rate due to gastrointestinal side effects in the pirfenidone groups (which could explain the lack of efficacy in the higher dose of pirfenidone in this trial), the absence of direct measurements of GFR, and a small sample size.

Nevertheless, these results clearly show that pirfenidone may be a promising agent for preventing decline in, or even improving, kidney function in diabetic nephropathy; however, larger-scale trials with hard clinical and renal outcomes are needed to confirm these findings.

Bardoxolone Methyl {#sec1_3}
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Bardoxolone methyl, a derivative of the natural product oleanolic acid, is an antioxidant inflammation modulator that can activate the Keap1-Nrf2 pathway, which leads to inhibition of the proinflammatory nuclear factor-κB pathway \[[@B8]\].

In a recent randomized double-blind placebo-controlled trial \[[@B9]\], the effects of three doses of bardoxolone methyl on eGFR in patients with type 2 diabetes and chronic kidney disease were assessed at 24 and 52 weeks. A total of 227 patients were randomly assigned to receive placebo or oral bardoxolone methyl at a dose of 25, 75, or 150 mg once daily for 52 weeks.

At 24 weeks, there was a significant improvement in the primary end point (change in eGFR from baseline) in all bardoxolone methyl groups, as compared with the placebo group, with mean differences of 8.2 ml/min/1.73 m^2^ in the 25 mg group, 11.4 ml/min/1.73 m^2^ in the 75 mg group, and 10.4 ml/min/1.73 m^2^ in the 150 mg group. Four weeks after the last administration of the study drug (at 56 weeks), the eGFR remained above the baseline value in patients receiving bardoxolone methyl. In the 75 mg and 150 mg groups, there was a slight but significant increase in the urinary ACR at 24 and 52 weeks. At 56 weeks, the ACR returned to the baseline level.

Again, one major limitation of this trial is the reliance on the surrogate primary end point (the change in eGFR) rather than direct renal clearance measurements.

Nevertheless, these results also clearly show that bardoxolone methyl may be a useful agent for the therapy of diabetic nephropathy. The confirmation of its clinical benefit will require a larger long-term study involving the assessment of various clinical outcomes. In October 2012, the late-stage trial BEACON of bardoxolone therapy was halted after an independent data-monitoring committee found excess serious adverse events and mortality in patients taking the drug.
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Diabetic nephropathy is associated with a decrease in the glycosaminoglycan composition of the glomerular basement membrane, particularly heparan sulfate. This loss of glomerular basement membrane integrity may aggravate proteinuria, and this may accelerate the progression of renal disease \[[@B10]\]. Sulodexide is a glycosaminoglycan extract of the porcine lung and liver; the primary components are low-molecular-weight heparin sulfate and dermatan sulfate. Some preliminary data suggested that orally administered sulodexide was capable of reducing urine albumin excretion in diabetic patients \[[@B11],[@B12]\]. However, in a large randomized double-blind placebo-controlled trial \[[@B13]\] involving 1,056 subjects with type 2 diabetes mellitus and microalbuminuria, sulodexide at a dose of 200 mg per day failed to decrease urine albumin excretion compared with placebo.

Pyridoxamine {#sec1_5}
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Pyridoxamine, a vitamin B6 derivative, is an effective scavenger of reactive oxygen species and a potent inhibitor of advanced glycation end products \[[@B14]\]. In a double-blind randomized placebo-controlled study \[[@B15]\], the efficacy of pyridoxamine dihydrochloride in delaying the progression of diabetic nephropathy was assessed. A total of 317 patients were randomly assigned to receive placebo, pyridoxamine dihydrochloride 150 mg twice daily, or pyridoxamine dihydrochloride 300 mg twice daily for 52 weeks. At the onset of the study, the mean serum creatinine level was 2.2 mg/dl, and the mean protein-to-creatinine ratio was 2,973 mg/g. The primary end point of the study was the change in the serum creatinine level from baseline.

At the end of the study period, there was no statistically significant difference in serum creatinine among the three groups. However, in the subgroup analysis, a significant treatment effect was noted for patients with mild renal impairment (serum creatinine 1.3--1.85 mg/dl) for both pyridoxamine dihydrochloride groups versus the placebo group.

The possibility that diabetic patients with less severe kidney impairment may benefit from pyridoxamine therapy remains to be investigated in an adequately powered trial addressing this specific subpopulation.

Paricalcitol {#sec1_6}
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Paricalcitol, a calcitriol analogue, is a vitamin D receptor activator. In animal models, activation of the vitamin D receptor suppressed TGF-β, reduced albuminuria, and slowed progression of kidney disease \[[@B16]\]. In a recent multinational placebo-controlled double-blind study \[[@B17]\], 281 diabetic patients with albuminuria were randomized to 24 weeks of treatment with paricalcitol 1 or 2 μg/day or placebo in addition to pre-existing ACEI or ARB therapy. At the end of the study period, the 2-μg dose was associated with a 20% decline in the urinary ACR compared to placebo.

Although the results of this study are encouraging, the clinical value of paricalcitol and other selective vitamin D receptor activators in the management of diabetic nephropathy will need to be confirmed by a larger prospective randomized trial with a longer duration, assessing effects on hard renal and cardiovascular outcomes.

Conclusions {#sec1_7}
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The encouraging results of some of the discussed agents will surely spark active research in this field, testing the above agents in long-term, hard-outcomes trials, like the BEACON trial \[[@B18]\], or other agents targeting other primary pathogenic mechanisms in diabetic nephropathy using antifibrotic agents such as anti-connective tissue growth factor monoclonal antibody \[[@B19]\] or anti-TGF-β monoclonal antibody \[[@B20]\]. Hopefully, we can fulfill the dream of significantly decreasing the burden of kidney disease in patients with diabetes mellitus by preventing, delaying, arresting, or even improving diabetic nephropathy \[[@B20]\].
